Compare GNLX & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLX | SRG |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.4M | 102.5M |
| IPO Year | 2022 | 2014 |
| Metric | GNLX | SRG |
|---|---|---|
| Price | $2.53 | $1.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $18.83 | N/A |
| AVG Volume (30 Days) | ★ 209.7K | 165.3K |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.47 | ★ 53.90 |
| EPS | ★ N/A | N/A |
| Revenue | $8,000.00 | ★ $18,204,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3.30 |
| 52 Week Low | $2.29 | $1.57 |
| 52 Week High | $8.54 | $4.38 |
| Indicator | GNLX | SRG |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 28.15 |
| Support Level | $2.32 | N/A |
| Resistance Level | $2.93 | $2.08 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 40.00 | 16.44 |
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.